Oncology Specialists, S.C.
12
0
0
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
25.0%
3 terminated/withdrawn out of 12 trials
75.0%
-11.5% vs industry average
0%
0 trials in Phase 3/4
111%
10 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere
Role: lead
VELCADE,Rituximab,Cyclophosphamide and Decadron
Role: lead
Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer
Role: lead
Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)
Role: lead
Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)
Role: lead
Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas
Role: lead
Non-Hodgkin Lymphoma in Elderly Patients Above the Age of 80 in the Rituximab Era
Role: lead
Oxaliplatin and Docetaxel as First-line Therapy for Advanced Non-small Cell Lung Cancer
Role: lead
Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients
Role: lead
Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer
Role: lead
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients
Role: lead
Pilot Clinical Trial (Phase II) of Inquiry-based Stress Reduction (IBSR) Program for Survivors of Breast Cancer
Role: collaborator
All 12 trials loaded